Enduring Material

Meeting the Complex Needs of Pustular Psoriasis
View Activity Info
Enter Basic User Info
View Content
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

6600 SW 92nd Ave., Suite 300
Portland, OR 97223-7195
General Information
Wednesday, November 18, 2020 - Friday, November 18, 2022
National Psoriasis Foundation
Virtual Conference Room
Psound Bytes: Difficult to Treat Series
National Psoriasis Foundation
Objectives
  • Understand the pathology of psoriatic disease, its manifestations and related comorbidities, indicating why it’s important to treat the disease to target.
  • Develop strategies for treating “difficult to treat” forms of psoriasis, including palmoplantar, guttate, genital, oral, nail and scalp psoriasis.
  • Select appropriate therapies for moderate to severe psoriatic disease based on current evidence for efficacy, safety and adherence, particularly with regard to difficult to treat cases.
Presentations and Speakers
Meeting the Complex Needs of Pustular Psoriasis
  • Kristina Callis Duffin, MD
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Meeting the needs of patients with GPP, PPP or PPPP can be challenging. Listen as Dr. Kristina Callis Duffin, Chair, Department of Dermatology at the University of Utah, discusses challenges from evaluation, the IL-36 RA gene, triggers, types, current treatment and what’s in the pipeline. This program is supported by unrestricted educational grants from AbbVie, Lilly and Ortho Dermatologics.
Disclosure Statements
Andi Agnew, NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.
Speakers:
Kristina Callis Duffin, MD has disclosed a relevant financial relationship with a commercial interest in the last 12 months:
  • Amgen//Celgene, Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, UCB, Boehringer-Ingelheim, Novartis - Grant/Research support recipient
  • Amgen, Abbvie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB, Boehringer-Ingelheim - Advisor or Consultant
All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
100 %
11/18/2020
Continue to Enduring Material